Clinical Trial Update: Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee. [Phase 3]

View source ↗

Summary

Phase 3 study of Ampion for severe knee osteoarthritis was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis of the Knee

Drugs mentioned

• Ampion

Snippet

Sponsor: Ampio Pharmaceuticals. Inc. | Conditions: Severe Osteoarthritis of the Knee | Phase 3 | Status: TERMINATED | Results posted: 2022-10-05